Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anbenitamab and Erfonrilimab in Resectable HER2+ Gastric Cancer
NCT06023758Phase 2Recruiting
- Sponsor
- Peking University
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anbenitamab, erfonrilimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Peking University. Started Sep 2023; status: recruiting.
02
Drugs
anbenitamaberfonrilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06023758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06023758.